Rumour has it that specialty pharma group Shire (SHP) is in advanced negotiations with US biotech group Baxalta (US:BXLT) about a possible takeover. Shire first made its interest in Baxalta known last year, but an offer was rejected in July, forcing it to turn hostile in August with a renewed all-stock offer worth $45.23 (£30.86) a share, equating to a total deal value of $30bn.
IC TIP:
Hold
at
4,441p
City analysts believe the revised offer could fall anywhere between $46.50 and $48 a share, and include a significant cash component to sweeten the deal for Baxalta shareholders.
